Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

FGFR4-high expression is associated with an immune-responsive phenotype in HCC and predicts inferior efficacy of lenvatinib plus PD-1 blockade.

BMC cancer - 8 May 2026

Wei Fuqun, Liu Weifu, Chen Zhisheng, Chen Zhongwu, Liu Jingfeng

Abstract excerpt

BACKGROUND: The LEAP-002 study showed that pembrolizumab plus lenvatinib did not provide statistically significant prognostic improvement over lenvatinib monotherapy in advanced hepatocellular carcinoma (HCC). This study investigated the potential protective role of high fibroblast growth factor receptor 4 (FGFR4) expression, a therapeutic target of lenvatinib, in immunotherapy for HCC. METHODS: The Kaplan Meier...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Antineoplastic Combined Chemotherapy Protocols
Share to Carcinoma, Hepatocellular

Methodology Data sources Editorial policy Privacy Delete account & data About Contact Helena Bioinformatics

Share to Immune Checkpoint Inhibitors

Share to Liver Neoplasms

Share to Phenylurea Compounds

Share to Programmed Cell Death 1 Receptor

Share to Quinolines

Share to Receptor, Fibroblast Growth Factor, Type 4

Source

Open in PubMed Open full text

Identifiers

PMID: 42104313
DOI: 10.1186/s12885-026-16098-9
PMCID: PMC13281259

Genes

FGFR4
CXCL1
CD274
CXCR2
JUN
PCDH1

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 8 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

FGFR4-high expression is associated with an immune-responsive phenotype in HCC and predicts inferior efficacy of lenvatinib plus PD-1 blockade.PMID 42104313Read ↗

Special issue "The advance of solid tumor research in China": FGFR4 alterations predict efficacy of immune checkpoint inhibitors in nonsmall cell lung cancer.Semantic proximity Read ↗

Fibroblast growth factor receptor 4 regulates proliferation, anti-apoptosis and alpha-fetoprotein secretion during hepatocellular carcinoma progression and represents a potential target for therapeutic intervention.Semantic proximity Read ↗

FGFR3 mutation characterization identifies prognostic and immune-related gene signatures in bladder cancer.Semantic proximity Read ↗

Oncogenic Potential of Replication Factor C Subunit 4: Correlations with Tumor Progression and Assessment of Potential InhibitorsSemantic proximity Read ↗

FGFR1 Promotes Tumor Immune Evasion via YAP-Mediated PD-L1 Expression Upregulation in Lung Squamous Cell CarcinomaSemantic proximity Read ↗

Gene expression profiling, prognosis, and immune microenvironment of KLF4 in malignanciesSemantic proximity Read ↗

High level of HDGF expression in hepatocellular carcinoma: a potential therapeutic target associated with prognosis and immune infiltrationSemantic proximity Read ↗

Elevated expression of TNFRSF4 impacts immune cell infiltration and gene mutation in hepatocellular carcinoma.Semantic proximity Read ↗

NRIR promotes immune escape in hepatocellular cancer by regulating IFNγ-induced PD-L1 expressionSemantic proximity Read ↗

Thirteen tumor necrosis factor receptor superfamily gene expression in malignancies and their clinical relevance to immunotherapy: a pan-cancer analysisSemantic proximity Read ↗

Multi-omics Analysis of Tumor Necrosis Factor Superfamily 4 Reveals Its Prognostic Value and T Cell Exhaustion Feature in CancerSemantic proximity Read ↗

Increased expression of Cyclin F in liver cancer predicts poor prognosis: A study based on TCGA database.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.